Literature DB >> 29607124

Consolidative ablative radiotherapy improves outcomes in oligometastatic non-small cell lung cancer: a further step toward new evidence.

Linda Agolli1,2, Stefano Arcangeli3.   

Abstract

Entities:  

Year:  2018        PMID： 29607124      PMCID： PMC5864636          DOI： 10.21037/jtd.2018.01.19

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 2.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

Review 3.  Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.

Authors:  Allison Ashworth; George Rodrigues; Gabriel Boldt; David Palma
Journal:  Lung Cancer       Date:  2013-08-20       Impact factor: 5.705

4.  Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.

Authors:  C Collen; N Christian; D Schallier; M Meysman; M Duchateau; G Storme; M De Ridder
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

Review 5.  Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Authors:  Oscar Juan; Sanjay Popat
Journal:  Clin Lung Cancer       Date:  2017-03-14       Impact factor: 4.785

6.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 7.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Authors:  Allison B Ashworth; Suresh Senan; David A Palma; Marc Riquet; Yong Chan Ahn; Umberto Ricardi; Maria T Congedo; Daniel R Gomez; Gavin M Wright; Giulio Melloni; Michael T Milano; Claudio V Sole; Tommaso M De Pas; Dennis L Carter; Andrew J Warner; George B Rodrigues
Journal:  Clin Lung Cancer       Date:  2014-05-15       Impact factor: 4.785

Review 8.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  Wilfried E E Eberhardt; Alan Mitchell; John Crowley; Haruhiko Kondo; Young Tae Kim; Andrew Turrisi; Peter Goldstraw; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

9.  Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.

Authors:  Linda Agolli; Maurizio Valeriani; Luca Nicosia; Stefano Bracci; Vitaliana De Sanctis; Giuseppe Minniti; Riccardo Maurizi Enrici; Mattia Falchetto Osti
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480

10.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.